Celecoxib[1]

Literatur

1 Dieser Beitrag wurde gefördert durch das BMBF (FKZ: 01EC0001)

• 1 Clemett D, Goa K . Celecoxib.  Drugs. 2000;  59 957-980
• 2 Food and Drug Administration. OPDRA Postmarketing Safety Review. Rockville, Md: FDA/Center for Drug Evaluation and Research; Feb 06, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_11_thrombo.doc
• 3 Mukherjee D, Nissen S E, Topol E J. Risk of cardiovascular events associated with selective COX-2 inhibitors.  JAMA. 2001;  286 954-959
• 4 Silverstein F E, Faich G. et al . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis.  JAMA. 2000;  284 1247-1255
• 5 Simon L S, Weaver A L. et al . Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized con-trolled trial.  JAMA. 1999;  282 1921-1928
• 6 Bensen W G, Fiechtner J J, McMillen J I. et al . Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.  Mayo Clin Proc. 1999;  74 1095-1105
• 7 Bolten W W. Scientific rationale for specific inhibition of COX-2.  J Rheumatol. 1998;  51 2-7 (Suppl)
• 8 Brater D C. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition.  Am J Med. 1999;  107 65S-70S, discussion 70S-71S
• 9 Clive D M, Stoff J S. Renal syndromes associated with nonsteroidal antiinflammatory drugs.  N Engl J Med. 1984;  310 563-572
• 10 Davies N M, McLachlan A J, Day R O, Williams K M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.  Clin Pharmacokinet. 2000;  38 225-242
• 11 FDA C LASS Advisory Committee. CLASS Advisory Committee Briefing Document. Rockville, Md: Food and Drug Administration Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_01_searle.pdf. Accessibility verified July 2, 2001 2001
• 12 FitzGerald G A, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2.  N Engl J Med. 2001;  345 433-442
• 13 Geis G S, Hubbard R C, Yu S. et al . Efficacy and tolerability of celecoxib: a comparison of once-daily vs twice-daily dosing (abstract).  Arthritis Rheum. 1999;  42 (Suppl) 144
• 14 Hubbard R C, Reis G S, Woods E M. et al .Efficacy and tolerability of celecoxib, a COX-2 specific inhibitor, for treating the pain and inflammation of osteoarthritis. Proceedings of the 18th Annual Meeting of the American Pain Society, Oct 21 - 24; Fort Lauderdale (FL) 1999: 613
• 15 Jackson L M, Hawkey C J. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages?.  Drugs. 2000;  59 1207-1216
• 16 Jones M K, Wang H, Peskar B M. et al . Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.  Nat Med. 1999;  5 1418-1423
• 17 Kistler T, Ambühl P M. Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion.  Swiss Med Wkly. 2001;  131 193-198
• 18 Maddrey W C, Maurath C J, Verburg K M, Geis G S. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.  Am J Ther. 2000;  7 153-158
• 19 Mahler J F, Davis B J, Morham S G, Langenbach R. Disruption of cyclooxygenase genes in mice.  Toxicol Pathol. 1996;  24 717-719
• 20 Mersfelder T L, Stewart L R. Warfarin and celecoxib interaction.  Ann Pharmacother. 2000;  34 325-327
• 21 Oliw E, Wollheim F A. New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results.  Läkartidningen. 2000;  97 2942-2944
• 22 Paulson S K, Vaughn M B, Jessen S M. et al . Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.  J Pharmacol Exp Ther. 2001;  297 638-645
• 23 Perazella M A, Eras J. Are selective COX-2 inhibitors nephrotoxic?.  Am J Kidney Dis. 2000;  35 937-940
• 24 Sanmuganathan P S, Ghahramani P, Jackson P R. et al . Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.  Heart. 2001;  85 265-271
• 25 Simon L S, Lanza F L, Lipsky P E. et al . Preliminary study of the safety and efficacy of SC-58 635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-con-trolled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.  Arthritis Rheum. 1998;  41 1591-1602
• 26 Takahashi Y, Roman C, Chemtob S. et al . Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo.  Am J Physiol Regul Integr Comp Physiol. 2000;  278 R1496-505
• 27 Tang C, Shou M, Rushmore T H. et al . In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.  Pharmacogenetics. 2001;  11 223-235
• 28 Whelton A, Maurath C J, Verburg K M, Geis G S. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.  Am J Ther. 2000;  7 159-175
• 29 Whelton A, Schulman G, Wallemark C. et al . Effects of celecoxib and naproxen on renal function in the elderly.  Arch Intern Med. 2000;  160 1465-1470
• 30 Zhao S Z, Dedhiya S D, Verburg K. et al . Celecoxib 200 mg administered once-a-day or in split doses has equal impact on health-related quality of life (HRQOL) of patients with osteoarthritis (OA) (abstract).  Arthritis Rheum. 1999;  42 (Suppl) 297
• 31 Zhao S Z, McMillen J I, Markenson J A. et al . Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib.  Pharmacotherapy. 1999;  19 1269-1278
• 32 Zhao S Z, Yu S S, Dedhiya S D. et al . Celecoxib improves health-related quality of life in patients with osteoarthritis of the knee (abstract).  Pharmacotherapy. 1999;  19 495